Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.

Begum NJ, Glatting G, Wester HJ, Eiber M, Beer AJ, Kletting P.

Sci Rep. 2019 Dec 27;9(1):20041. doi: 10.1038/s41598-019-56603-8.

2.

Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA-inhibitors.

Wurzer A, DiCarlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, Wester HJ.

J Nucl Med. 2019 Dec 20. pii: jnumed.119.234922. doi: 10.2967/jnumed.119.234922. [Epub ahead of print]

PMID:
31862804
3.

Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?

Hensbergen AW, van Willigen DM, van Beurden F, van Leeuwen PJ, Buckle T, Schottelius M, Maurer T, Wester HJ, van Leeuwen FWB.

Bioconjug Chem. 2020 Jan 6. doi: 10.1021/acs.bioconjchem.9b00758. [Epub ahead of print]

PMID:
31855410
4.

Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, 18F- rhPSMA-7, in Patients with Prostate Cancer.

Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Krönke M, Herz M, Kropf S, Wester HJ, Weber WA, Eiber M.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234609. doi: 10.2967/jnumed.119.234609. [Epub ahead of print]

PMID:
31836686
5.

18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.

Eiber M, Krönke M, Wurzer A, Ulbrich L, Jooß L, Maurer T, Horn T, Schiller K, Langbein T, Buschner G, Wester HJ, Weber WA.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234914. doi: 10.2967/jnumed.119.234914. [Epub ahead of print]

PMID:
31836682
6.

Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer.

Krönke M, Wurzer A, Schwamborn K, Ulbrich L, Jooß L, Maurer T, Horn T, Rauscher I, Haller B, Herz M, Wester HJ, Weber WA, Eiber M.

J Nucl Med. 2019 Dec 13. pii: jnumed.119.234906. doi: 10.2967/jnumed.119.234906. [Epub ahead of print]

PMID:
31836681
7.

Prostate-Specific Membrane Antigen-Guided Surgery.

Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, Wester HJ, van Leeuwen FWB.

J Nucl Med. 2020 Jan;61(1):6-12. doi: 10.2967/jnumed.119.232330. Epub 2019 Nov 15.

PMID:
31732677
8.

Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance.

van Leeuwen FWB, Schottelius M, Brouwer OR, Vidal-Sicart S, Achilefu S, Klode J, Wester HJ, Buckle T.

J Nucl Med. 2020 Jan;61(1):13-19. doi: 10.2967/jnumed.119.228684. Epub 2019 Nov 11.

PMID:
31712326
9.

Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals.

Borchert T, Beitar L, Langer LBN, Polyak A, Wester HJ, Ross TL, Hilfiker-Kleiner D, Bengel FM, Thackeray JT.

J Nucl Cardiol. 2019 Oct 28. doi: 10.1007/s12350-019-01929-z. [Epub ahead of print]

PMID:
31659697
10.

Imaging Inflammation in Atherosclerosis with CXCR4-directed 68Ga-Pentixafor PET/CT - Correlation with 18F-FDG PET/CT.

Kircher M, Tran-Gia J, Kemmer L, Zhang X, Schirbel A, Werner RA, Buck AK, Wester HJ, Hacker M, Lapa C, Li X.

J Nucl Med. 2019 Oct 25. pii: jnumed.119.234484. doi: 10.2967/jnumed.119.234484. [Epub ahead of print]

PMID:
31653710
11.

68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.

Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, Bandurski T, Lass P, Krebs M, Połom W, Matuszewski M, Wester HJ, Buck AK, Kübler H, Lapa C.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):168-177. doi: 10.1007/s00259-019-04524-z. Epub 2019 Sep 16.

PMID:
31529265
12.

Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.

Hensbergen AW, Buckle T, van Willigen DM, Schottelius M, Welling MM, van der Wijk FA, Maurer T, van der Poel HG, van der Pluijm G, van Weerden WM, Wester HJ, van Leeuwen FWB.

J Nucl Med. 2020 Feb;61(2):234-241. doi: 10.2967/jnumed.119.233064. Epub 2019 Sep 3.

PMID:
31481575
13.

CXCR4-Directed Imaging in Solid Tumors.

Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, Buck AK, Pomper MG, Rowe SP, Lapa C.

Front Oncol. 2019 Aug 14;9:770. doi: 10.3389/fonc.2019.00770. eCollection 2019.

14.

From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.

Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP.

Semin Nucl Med. 2019 Sep;49(5):422-437. doi: 10.1053/j.semnuclmed.2019.06.002. Epub 2019 Jul 6. Review.

PMID:
31470935
15.

Click Chemistry in the Design and Production of Hybrid Tracers.

Hensbergen AW, van Willigen DM, Welling MM, van der Wijk FA, de Korne CM, van Oosterom MN, Schottelius M, Wester HJ, Buckle T, van Leeuwen FWB.

ACS Omega. 2019 Jul 22;4(7):12438-12448. doi: 10.1021/acsomega.9b01484. eCollection 2019 Jul 31.

16.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.

PMID:
31440799
17.

Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo.

Schottelius M, Ludescher M, Richter F, Kapp TG, Kessler H, Wester HJ.

EJNMMI Res. 2019 Aug 13;9(1):75. doi: 10.1186/s13550-019-0545-2.

18.

Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses.

Rieckmann M, Delgobo M, Gaal C, Büchner L, Steinau P, Reshef D, Gil-Cruz C, Horst ENT, Kircher M, Reiter T, Heinze KG, Niessen HW, Krijnen PA, van der Laan AM, Piek JJ, Koch C, Wester HJ, Lapa C, Bauer WR, Ludewig B, Friedman N, Frantz S, Hofmann U, Ramos GC.

J Clin Invest. 2019 Aug 13;130:4922-4936. doi: 10.1172/JCI123859.

19.

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI.

Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME.

Theranostics. 2019 May 27;9(12):3653-3658. doi: 10.7150/thno.31032. eCollection 2019.

20.

[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas.

Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C, Schirbel A, Rowe SP, Pomper MG, Buck AK, Wester HJ, Ernestus RI, Lapa C.

Front Oncol. 2019 Jun 12;9:503. doi: 10.3389/fonc.2019.00503. eCollection 2019.

21.

PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.

Wester HJ, Schottelius M.

Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30. Review.

PMID:
31227053
22.

[68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery.

Li X, Yu W, Wollenweber T, Lu X, Wei Y, Beitzke D, Wadsak W, Kropf S, Wester HJ, Haug AR, Zhang X, Hacker M.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1616-1625. doi: 10.1007/s00259-019-04322-7. Epub 2019 Apr 19.

23.

Radiosynthesis and pre-clinical evaluation of [68Ga] labeled antimicrobial peptide fragment GF-17 as a potential infection imaging PET radiotracer.

Chopra S, Singh B, Koul A, Mishra AK, Robu S, Kaur A, Ghai A, Caplash N, Wester HJ.

Appl Radiat Isot. 2019 Jul;149:9-21. doi: 10.1016/j.apradiso.2019.04.008. Epub 2019 Apr 10.

PMID:
31003040
24.

Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.

Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T.

Eur Urol. 2019 Oct;76(4):517-523. doi: 10.1016/j.eururo.2019.03.045. Epub 2019 Apr 12.

PMID:
30987843
25.

Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.

Maurer S, Herhaus P, Lippenmeyer R, Hänscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C.

J Nucl Med. 2019 Oct;60(10):1399-1405. doi: 10.2967/jnumed.118.223420. Epub 2019 Mar 8.

PMID:
30850502
26.

Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.

Reichart F, Maltsev OV, Kapp TG, Räder AFB, Weinmüller M, Marelli UK, Notni J, Wurzer A, Beck R, Wester HJ, Steiger K, Di Maro S, Di Leva FS, Marinelli L, Nieberler M, Reuning U, Schwaiger M, Kessler H.

J Med Chem. 2019 Feb 28;62(4):2024-2037. doi: 10.1021/acs.jmedchem.8b01588. Epub 2019 Feb 6.

PMID:
30657681
27.

Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.

Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C.

Strahlenther Onkol. 2019 May;195(5):420-429. doi: 10.1007/s00066-018-1417-9. Epub 2019 Jan 4.

PMID:
30610354
28.

Entering the era of molecular-targeted precision surgery in recurrent prostate cancer.

Maurer T, van Leeuwen FWB, Schottelius M, Wester HJ, Eiber M.

J Nucl Med. 2018 Dec 20. pii: jnumed.118.221861. doi: 10.2967/jnumed.118.221861. [Epub ahead of print] No abstract available.

29.

Fully Automated 89Zr Labeling and Purification of Antibodies.

Poot AJ, Adamzek KWA, Windhorst AD, Vosjan MJWD, Kropf S, Wester HJ, van Dongen GAMS, Vugts DJ.

J Nucl Med. 2019 May;60(5):691-695. doi: 10.2967/jnumed.118.217158. Epub 2018 Dec 7.

PMID:
30530830
30.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
31.

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M.

Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.

PMID:
30473431
32.

Correction: 18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.

Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH.

Mol Psychiatry. 2018 Nov 21. doi: 10.1038/s41380-018-0302-3. [Epub ahead of print]

PMID:
30464328
33.

Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R.

J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15.

PMID:
30442756
34.

Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.

Bouter Y, Meller B, Sahlmann CO, Wolf BJ, Langer L, Bankstahl JP, Wester HJ, Kropf S, Meller J, Bouter C.

Nuklearmedizin. 2018 Sep;57(5):198-203. doi: 10.3413/Nukmed-0971-18-04. Epub 2018 Sep 28.

PMID:
30267402
35.

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.

Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ.

J Nucl Med. 2019 Jan;60(1):71-78. doi: 10.2967/jnumed.118.212720. Epub 2018 Sep 20.

36.

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S.

Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388. Review.

37.

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.

Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104. doi: 10.1016/j.ijrobp.2018.08.066. Epub 2018 Sep 7.

PMID:
30201438
38.

PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.

Vag T, Steiger K, Rossmann A, Keller U, Noske A, Herhaus P, Ettl J, Niemeyer M, Wester HJ, Schwaiger M.

EJNMMI Res. 2018 Sep 6;8(1):90. doi: 10.1186/s13550-018-0442-0.

39.

Chemokine Receptor 4 Expression in Primary Sjögren's Syndrome.

Cytawa W, Kircher S, Schirbel A, Shirai T, Fukushima K, Buck AK, Wester HJ, Lapa C.

Clin Nucl Med. 2018 Nov;43(11):835-836. doi: 10.1097/RLU.0000000000002258.

PMID:
30179908
40.

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity.

Wirtz M, Schmidt A, Schottelius M, Robu S, Günther T, Schwaiger M, Wester HJ.

EJNMMI Res. 2018 Aug 22;8(1):84. doi: 10.1186/s13550-018-0440-2.

41.

18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.

Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH.

Mol Psychiatry. 2018 Aug 17. doi: 10.1038/s41380-018-0203-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2018 Nov 21;:.

PMID:
30120417
42.

CXCR4-directed theranostics in oncology and inflammation.

Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C.

Ann Nucl Med. 2018 Oct;32(8):503-511. doi: 10.1007/s12149-018-1290-8. Epub 2018 Aug 13. Review.

43.

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics.

Šimeček J, Hermann P, Seidl C, Bruchertseifer F, Morgenstern A, Wester HJ, Notni J.

EJNMMI Res. 2018 Aug 8;8(1):78. doi: 10.1186/s13550-018-0431-3.

44.

Effect of Carbohydration on the Theranostic Tracer PSMA I&T.

Schmidt A, Wirtz M, Färber SF, Osl T, Beck R, Schottelius M, Schwaiger M, Wester HJ.

ACS Omega. 2018 Jul 31;3(7):8278-8287. doi: 10.1021/acsomega.8b00790. Epub 2018 Jul 25.

45.

Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6.

Färber SF, Wurzer A, Reichart F, Beck R, Kessler H, Wester HJ, Notni J.

ACS Omega. 2018 Feb 28;3(2):2428-2436. doi: 10.1021/acsomega.8b00035.

46.

Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.

Wurzer A, Pollmann J, Schmidt A, Reich D, Wester HJ, Notni J.

Mol Pharm. 2018 Sep 4;15(9):4296-4302. doi: 10.1021/acs.molpharmaceut.8b00602. Epub 2018 Jul 27.

PMID:
30011372
47.

Targeting Chemokine Receptor CXCR4 and Translocator Protein for Characterization of High-Risk Plaque in Carotid Stenosis Ex Vivo.

Grosse GM, Bascuñana P, Schulz-Schaeffer WJ, Teebken OE, Wilhelmi M, Worthmann H, Ross TL, Wester HJ, Kropf S, Derlin T, Bengel FM, Bankstahl JP, Weissenborn K.

Stroke. 2018 Aug;49(8):1988-1991. doi: 10.1161/STROKEAHA.118.021070.

PMID:
30002148
48.

Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT.

Derlin T, Sedding DG, Dutzmann J, Haghikia A, König T, Napp LC, Schütze C, Owsianski-Hille N, Wester HJ, Kropf S, Thackeray JT, Bankstahl JP, Geworski L, Ross TL, Bauersachs J, Bengel FM.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1934-1944. doi: 10.1007/s00259-018-4076-2. Epub 2018 Jul 3.

49.

Anti-Inflammatory Effects on Atherosclerotic Lesions Induced by CXCR4-Directed Endoradiotherapy.

Li X, Kemmer L, Zhang X, Kircher M, Buck AK, Wester HJ, Hacker M, Lapa C.

J Am Coll Cardiol. 2018 Jul 3;72(1):122-123. doi: 10.1016/j.jacc.2018.04.035. No abstract available.

50.

Equilibrium Thermodynamics, Formation, and Dissociation Kinetics of Trivalent Iron and Gallium Complexes of Triazacyclononane-Triphosphinate (TRAP) Chelators: Unraveling the Foundations of Highly Selective Ga-68 Labeling.

Vágner A, Forgács A, Brücher E, Tóth I, Maiocchi A, Wurzer A, Wester HJ, Notni J, Baranyai Z.

Front Chem. 2018 May 23;6:170. doi: 10.3389/fchem.2018.00170. eCollection 2018.

Supplemental Content

Loading ...
Support Center